Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project

Santos García, Diego; Blázquez-Estrada, Marta; Calopa, Matilde; Escamilla-Sevilla, Francisco; Freire, Eric; García Ruiz, Pedro J.; Grandas, Francisco; Kulisevsky, Jaime; López-Manzanares, Lydia; Martínez Castrillo, Juan Carlos; Mir, Pablo; Pagonabarraga, Javier; Pérez-Errazquin, Francisco; Salom, José María; Tijero, Beatriz; Valldeoriola, Francesc; Yáñez, Rosa; Avilés, Arantxa; Luquín, María-Rosario

Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000–150.000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on patients’ and caregivers’ lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. According to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.